Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reference Product Sample Abuses: Indian Firms Flag Concerns With FTC

Executive Summary

Indian generic firms appear to be weighing in on controversy around brand name company tactics in the US to block access to reference products for bioequivalence testing – but generic firms may ultimately need legislation to resolve their concerns.

You may also be interested in...



Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.

FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene

FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.

India Lockdown: Early Signs of Manufacturing Strains But Resolutions Underway

Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’

Topics

Related Companies

UsernamePublicRestriction

Register

GB002049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel